MA GENERAL HOSP is a generic drug manufacturer focused on Oncology, Neurology.
Upcoming FDA Decisions
Full Calendar →MA GENERAL HOSP's Key Drugs
MA GENERAL HOSP's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
MA GENERAL HOSP's Recent FDA Approvals
New NDA/BLA approvals for MA GENERAL HOSP over the last two years — novel drugs only, excluding generics and label supplements.
MA GENERAL HOSP's Therapeutic Areas
MA GENERAL HOSP's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MA GENERAL HOSP's Top Competitors
MA GENERAL HOSP's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MA GENERAL HOSP Pipeline Snapshot
Active clinical trials for MA GENERAL HOSP across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2014-09-25
- Latest
- 2021-02-24
- Applications
- 1